Ron leads technology development in gene editing at Life Edit Therapeutics. He has more than 25 years of experience in the biotech industry, focusing on developing and applying innovative protein platforms for enzyme and protein therapeutic applications.
Prior to joining Life Edit, Ron led engineering efforts as a Director of Platform Development at a CRISPR startup, Arbor Biotechnologies. Prior to this, Ron spent 20 years at New England Biolabs (NEB) leading a research group engineering enzymes and developing protein platforms that enable high throughput cell-free protein synthesis and assay.
Ron received his Ph.D. in Pharmacognosy (Medicinal Chemistry) from the University of Michigan at Ann Arbor and B.S. in Biochemistry and Plant Physiology from Peking University in Beijing, China.
